Oral bLF administration enhanced anemia which is a very common chemotherapy related side effect; as results have shown, there were significant increases in RBCs count and serum Hb in patients in test group 3 months after treatment compared to patients in control group (P ≤ 0.05). Here, GSTM1 is linked to anemia (phenotype).